Albumedix enters evaluation agreement with Novartis

By Maggie Lynch contact

- Last updated on GMT


Related tags: Evaluation, Drug delivery, Novartis

Novartis will use Albumedix’s Veltis drug delivery technology platform to develop several first-in-class therapeutics.

“Our Veltis technology platform offers multiple drug enhancement modalities for the development of more effective, safer and convenient therapeutics,” ​Jonas Skjodt Moller, COO of Albumedix, told us.

The platform, based on Albumedix’s engineered human albumin variant, has attracted interest by pharma and biotech companies looking to further enhance drug candidates, said Moller.

He continued, “Among other functional attributes this includes its validated capability to significantly prolong the duration of action of associated compounds.”

The agreement with Novartis covers the use of Albumedix technology across a range of molecules, targets, and mechanisms. Novartis could not comment further.

“We are very excited to be working with likeminded researchers at Novartis and see this as yet another step towards unlocking the full potential of albumin,”​ Moller said.

Related news

Related products

show more

Stability Testing As a Quality Control Measure

Stability Testing As a Quality Control Measure

Frontage Laboratories | 19-Jun-2019 | Technical / White Paper

Stability testing is, in essence, a quality control process and is there¬fore a vital component of every phase of clinical development for both large and...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more